Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Reuters

昨天

Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545744702"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545744702\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545744702?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545744702","market":"us","top_or_hot":-1,"title":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 04:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL6JFmrN:1","article_id":"2545744702","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545744702","pubTimestamp":1750710882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx. Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty . This funding comes after the first commercial sale of YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","UTHR":"美国联合医疗","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4532":"文艺复兴科技持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LQDA":"Liquidia Technologies Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"Liquidia Corporation在YUTREPIA成功推出后扩大了制造能力，并从HCRx获得了5000万美元的额外资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":0.9,"NDAQ":0.9,"LQDA":0.9},"content_text":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    \n\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}